A Phase 3 interventional study of Apixaban and Enoxaparin in Venous Thrombosis and Pulmonary Embolism, sponsored by Bristol-Myers Squibb. Completed at 297 sites in 35 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-12-08.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.
Among the 26 studies testing apixaban in Venous Thrombosis, this one has the largest enrollment, is one of 2 that started in 2007, is one of 10 in phase 3, and was the 4th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:
Rushad Patell · Sites in United States
Ages 18+
Clinical Urology and Epidemiology Working Group · Sites in Finland
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
James Bayley · Sites in United States
Ages 18+
University Hospital, Geneva
Ages 18–120
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 12 · Phase 4 10
First in 2004; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6,758 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 445 across the 26 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 26 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 9 studies filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
3 of the studies testing apixaban in Venous Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
| NCT07713875James BayleyExtended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies testing apixaban in Venous Thrombosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur within patients hospitalized for acute medical illness, and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. The safety of apixaban will also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
While hospitalized, Apixaban plus Placebo Apixaban (Tablets, Oral, 2.5 mg), Placebo (Syringes, SC) After hospital discharge, Apixaban Apixaban (Tablets, Oral, 2.5 mg)
Drug: Apixaban
While hospitalized, Enoxaparin plus Placebo Enoxaparin (Syringes, SC, 40 mg), Placebo (Tablets, Oral) After hospital discharge: Placebo Placebo (Tablets, Oral)
Drug: Enoxaparin
Apixaban: Twice daily, 30 days Placebo: Once daily, 6-14 days
Also known as: BMS-562247
Enoxaparin: Once daily, 6-14 days Placebo: Twice daily, 30 days
Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population
VTE: nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE could not be excluded as a cause. Intended Treatment Period=period that started on day of randomization: period ended (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; period ended (for not treated) 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. All efficacy events were adjudicated by the Independent Central Adjudication Committee (ICAC). Event rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Major Bleeding During the Treatment Period in Treated Participants
Major bleeding was adjudicated by an ICAC using criteria from the International Society on Thrombosis and Hemostasis (ISTH) and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or bleeding in a critical site or bleeding which is fatal. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Day 1, first dose of study drug, to last dose of study drug plus 2 days
Incidence of Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants
Bleeding was adjudicated by an ICAC using criteria from the ISTH. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis, if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for bleeding endpoints. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Day 1, first dose of study drug, to last dose of study drug plus 2 days
Incidence of Composite of Major or Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants
Bleeding was adjudicated by an ICAC using criteria from the ISTH. Major bleeding: acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or bleeding in a critical site or bleeding which is fatal. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage; rectal blood loss. Treatment Period=onset from first dose of study drug through 2 days after last dose of study drugs. Incidence: Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Day 1, first dose of study drug, to last dose of study drug plus 2 days
Incidence of All Bleeding During the Treatment Period in Treated Participants
Bleeding was adjudicated by an ICAC using criteria from the ISTH. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs, for bleeding endpoints. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Day 1, first dose of drug to last dose of drug plus 2 days
Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Key Secondary Efficacy Evaluable Participants
Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Key Secondary Efficacy population: all who received at least 1 dose of parenteral study drug and: (those without suspected VTE events during Parenteral Treatment) had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or (those with suspected VTE events during Parenteral Treatment) had those suspected VTE events adjudicated as non-events, and had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or had an adjudicated total VTE during Parenteral Treatment; or had an adjudicated VTE-related death during Parenteral Treatment. Event rate (%): n/N\*100 (n=number with observation; N=total secondary efficacy evaluable participants).
Time frame: Day 1 to last dose of parenteral study drug plus 1 day
Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Secondary Efficacy Evaluable Participants
Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Secondary Efficacy Evaluable includes those who had an adjudicated, evaluable ultrasound at end of parenteral treatment and for those with a suspected symptomatic event, the result of the adjudication for the symptomatic event was not inadequate; or those with an adjudicated event that was part of the composite endpoint.. Event rate (%): n/N\*100 (n=number with observation; N=total secondary efficacy evaluable participants).
Time frame: Day 1 to last dose of parenteral study drug plus 1 day
Incidence of Adjudicated Total VTE or All-Cause Death With Onset During the Intended Treatment Period
Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal (N-F) PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. All-Cause Death (A-C Death). Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Adjudicated Proximal DVT, Non-Fatal PE or All-Cause Death With Onset During the Intended Treatment Period
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Adjudicated Proximal DVT, Non-Fatal PE or VTE-Related Death, With Onset During the Intended Treatment Period
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Adjudicated VTE-Related Death With Onset During the Intended Treatment Period in Randomized Participants
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Adjudicated Symptomatic VTE or All-Cause Death With Onset During the Intended Treatment Period
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Symptomatic Adjudicated VTE or VTE-Related Death With Onset During the Intended Treatment Period
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of All VTE or Major Bleeding or All-Cause Death During the Intended Treatment Period
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Adjudicated PE With Onset During the Intended Treatment Period
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. PE: non-fatal or fatal. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Adjudicated Non-Fatal PE With Onset During the Intended Treatment Period
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Adjudicated Symptomatic DVT With Onset During the Intended Treatment Period
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Adjudicated Proximal DVT With Onset During the Intended Treatment Period
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Adjudicated Symptomatic Distal DVT With Onset During the Intended Treatment Period
Events were adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Adjudicated Symptomatic Proximal DVT With Onset During the Intended Treatment Period
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Incidence of Adjudicated Asymptomatic Proximal DVT With Onset During the Intended Treatment Period
A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
Time frame: Intended Treatment Period
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Deaths, and Discontinuations Due to AEs During the Treatment Period in Treated Participants
Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for AEs, and 30 days after last dose of study drugs for SAEs and deaths.
Time frame: Day 1, first dose of study drug, to last dose of study drug plus 2 days (AEs), plus 30 days (SAEs, Deaths)
Mean Change From Baseline in Diastolic Blood Pressure in Treated Participants During Treatment Period
Diastolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken with the participant either sitting, standing, or supine.
Time frame: Day 1 to last dose of study drug plus 2 days
Mean Change From Baseline in Systolic Blood Pressure in Treated Participants During Treatment Period
Systolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken either sitting, standing, or supine.
Time frame: Day 1 to last dose of study drug plus 2 days
Mean Change From Baseline in Heart Rate in Treated Participants
Heart Rate was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Heart rate was measured in beats per minute (bpm) and could have been taken with participants either sitting, standing, or supine.
Time frame: Day 1 to last dose of study drug plus 2 days
Number of Participants With Marked Abnormalities in Hematology Laboratory Tests During Treatment Period in Treated Participants
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). Absolute (Abs). Hemoglobin: \>2 g/dL decrease compared to PreRx value or value \<=8 g/dL; Hematocrit: \<0.75\*PreRx; Erythrocytes: \<0.75\*PreRx c/µL; Leukocytes: \<0.75\*LLN or \> 1.25\*ULN, if PreRx \<LLN then use \<0.8\*PreRx or \>ULN, if PreRx \>ULN then use \>1.2\*PreRx or \< LLN; Platelet count: \< 100\*10\^9 c/L; ANC: \< 1.00\*10\^3 c/µL; Abs eosinophils: \> 0.75\*10\^3 c/µL; Abs Basophils: \> 400/MM\^3; Abs Monocytes \> 2000/MM\^3; Abs Lymphocytes: \< 0.750\*10\*3 c/ µL or \> 7.5\*10\^3 c/ µL. Samples were obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.
Time frame: Day 1 to last dose of study drug plus 2 days
Number of Participants With Marked Abnormalities in Electrolyte Laboratory Tests During Treatment Period in Treated Participants
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: \< 0.75\*LLN or \> 1.25\*ULN, or if PreRx \< LLN then use \< 0.75\* PreRx or \> ULN if PreRx \> ULN then use \> 1.25\*PreRx or \< LLN; Serum Calcium mg/dL Low/High: \< 0.8\*LLN or \> 1.2\*ULN, or if PreRx \< LLN then use \< 0.75\*PreRx or \> ULN if PreRx \> ULN then use \> 1.25\*PreRx or \< LLN; Serum Chloride mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use \< 0.9\*PreRx or \> ULN if PreRx \> ULN then use \> 1.1\*PreRx or \< LLN; Serum Potassium mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use \< 0.9\*PreRx or \> ULN if PreRx \> ULN then use \> 1.1\*PreRx or \< LLN; Serum Sodium mEq/L: \< 0.95\*LLN or \> 1.05\*ULN, or if PreRx \< LLN then use \< 0.95\*PreRx or \> ULN if PreRx \> ULN then use \> 1.05\*PreRx or \< LLN. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.
Time frame: Day 1 to last dose of study drug plus 2 days
Number of Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests During the Treatment Period in Treated Participants
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL \> 1.5\*ULN; Creatinine mg/dL: \> 1.5\*ULN; Alanine aminotransferase (ALT) U/L: \> 3\*ULN; Aspartate aminotransferase (AST) U/L: \> 3\*ULN; Alkaline phosphatase U/L: \> 2\*ULN; Bilirubin Direct mg/dL: \> 1.5\*ULN; Bilirubin Total mg/dL: \> 2\*ULN. Samples for laboratories obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.
Time frame: Day 1 to last dose of study drug plus 2 days
Number of Participants With Marked Abnormalities in Glucose, Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests During the Treatment Period in Treated Participants
Creatine kinase High: \>5\*ULN Units/Liter (U/L); Total Protein High/Low: \< 0.9 \*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use 0.9\* PreRx or \> ULN if PreRx \> ULN then use 1.1 \*PreRx or \<LLN; Uric acid High: \> 1.5\* ULN, or if PreRx \> ULN then use \> 2 \*PreRx. Glucose Fasting: \<0.9\*LLN or \> 1.5\*ULN or if PreRx \< LLN then use \< 0.8\*PreRx or \> ULN, if PreRx \> ULN then use \>2.0\*PreRx. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) ± 2days.
Time frame: Day 1 to last dose of study drug plus 2 days
Incidence of Events of Special Interest of Adjudicated Myocardial Infarction, Stroke, and Thrombocytopenia During the Treatment Period in Treated Participants
Events of Special Interest include: adjudicated thrombocytopenia, adjudicated myocardial infarction (MI), adjudicated stroke, and adjudicated MI or stroke. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants). Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs.
Time frame: Day 1 to last dose of study drug plus 2 days
Number of Participants With Events of Special Interest for Liver Function and Neurology During Treatment Period in Treated Participants With Available Measurements
Special interest include: liver function test increases, AEs related to liver function, and neurologic AEs. Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drug when summarizing AEs and through 30 days after the last dose when summarizing SAEs.
Time frame: Day 1 to last dose of study drug plus 2 days (AEs) and plus 30 days (SAEs)
Number of Participants With Liver-Related Elevations During the Treatment Period in Treated Participants
Liver function tests: Alanine aminotransferase (ALT) U/L; Aspartate aminotransferase (AST) U/L; Alkaline phosphatase U/L; Total Bilirubin (TBili) mg/dL. Elevations consist of \>3\*Upper Limit of Normal (ULN) for ALT and AST and elevation of \>2\*ULN for Bilirubin.
Time frame: Day 1 to last dose of study drug plus 2 days
First patient, first visit was June 2007 and last patient, last visit was May 2011. Acutely ill patients who had been hospitalized and had an expected hospitalization of an additional 3 or more days after randomization were enrolled.
| Milestone | Apixaban 2.5 mg Oral | Enoxaparin 40 mg Subcutaneous |
|---|---|---|
| Started | 3255 | 3273 |
| Completed | 2442 | 2516 |
| Not completed | 813 | 757 |
| Withdrew: Death | 40 | 47 |
| Withdrew: Adverse event | 284 | 260 |
| Withdrew: Withdrawal by subject | 299 | 271 |
| Withdrew: Lost to follow-up | 72 | 71 |
| Withdrew: Poor/non-compliance | 46 | 33 |
| Withdrew: No longer met criteria | 41 | 37 |
| Withdrew: Administrative reason by sponsor | 1 | 0 |
| Withdrew: Non-specified | 29 | 38 |
| Withdrew: Treated for 1 day; missing status/reason | 1 | 0 |
VTE: nonfatal pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE could not be excluded as a cause. Intended Treatment Period=period that started on day of randomization: period ended (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; period ended (for not treated) 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. All efficacy events were adjudicated by the Independent Central Adjudication Committee (ICAC). Event rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Composite of Adjudicated Total Venous Thromboembolism (VTE) and VTE-related Death During the Intended Treatment Period - Primary Efficacy Population | 2.71 (2.11 to 3.49) | 3.06 (2.43 to 3.86) |
Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Key Secondary Efficacy population: all who received at least 1 dose of parenteral study drug and: (those without suspected VTE events during Parenteral Treatment) had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or (those with suspected VTE events during Parenteral Treatment) had those suspected VTE events adjudicated as non-events, and had an adjudicated evaluable ultrasound performed at the end of Parenteral Treatment; or had an adjudicated total VTE during Parenteral Treatment; or had an adjudicated VTE-related death during Parenteral Treatment. Event rate (%): n/N\*100 (n=number with observation; N=total secondary efficacy evaluable participants).
| Event rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Key Secondary Efficacy Evaluable Participants | 1.73 (1.28 to 2.33) | 1.61 (1.18 to 2.19) |
Parenteral study drug=active or placebo enoxaparin. Parenteral treatment: started on the first dose of parenteral study drug and ended the day after the last dose of parenteral study drug. Secondary Efficacy Evaluable includes those who had an adjudicated, evaluable ultrasound at end of parenteral treatment and for those with a suspected symptomatic event, the result of the adjudication for the symptomatic event was not inadequate; or those with an adjudicated event that was part of the composite endpoint.. Event rate (%): n/N\*100 (n=number with observation; N=total secondary efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Total VTE and VTE-Related Death During Parenteral Treatment in Secondary Efficacy Evaluable Participants | 1.66 (1.22 to 2.28) | 1.51 (1.09 to 2.10) |
Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal (N-F) PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. All-Cause Death (A-C Death). Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Total VTE or All-Cause Death With Onset During the Intended Treatment Period | 6.44 (5.51 to 7.53) | 6.63 (5.69 to 7.71) |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Proximal DVT, Non-Fatal PE or All-Cause Death With Onset During the Intended Treatment Period | 6.44 (5.51 to 7.53) | 6.50 (5.58 to 7.58) |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Proximal DVT, Non-Fatal PE or VTE-Related Death, With Onset During the Intended Treatment Period | 2.71 (2.11 to 3.49) | 2.93 (2.32 to 3.72) |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated VTE-Related Death With Onset During the Intended Treatment Period in Randomized Participants | 0.06 (0.00 to 0.24) | 0.09 (0.02 to 0.29) |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Symptomatic VTE or All-Cause Death With Onset During the Intended Treatment Period | 3.11 (2.56 to 3.77) | 3.46 (2.88 to 4.14) |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Symptomatic Adjudicated VTE or VTE-Related Death With Onset During the Intended Treatment Period | 0.40 (0.23 to 0.69) | 0.80 (0.54 to 1.17) |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. VTE: nonfatal PE, symptomatic DVT, or asymptomatic proximal DVT detected by ultrasound. VTE-related death: fatal PE or sudden death for which VTE cannot be excluded as a cause. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of All VTE or Major Bleeding or All-Cause Death During the Intended Treatment Period | 7.16 (6.18 to 8.29) | 6.83 (5.88 to 7.93) |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. PE: non-fatal or fatal. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated PE With Onset During the Intended Treatment Period | 0.22 (0.10 to 0.46) | 0.24 (0.12 to 0.50) |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Non-Fatal PE With Onset During the Intended Treatment Period | 0.22 (0.10 to 0.46) | 0.24 (0.12 to 0.50) |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Symptomatic DVT With Onset During the Intended Treatment Period | 0.15 (0.06 to 0.37) | 0.49 (0.30 to 0.80) |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Proximal DVT With Onset During the Intended Treatment Period | 2.40 (1.84 to 3.14) | 2.50 (1.94 to 3.24) |
Events were adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Symptomatic Distal DVT With Onset During the Intended Treatment Period | 0.00 (0.00 to 0.15) | 0.15 (0.06 to 0.37) |
Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Symptomatic Proximal DVT With Onset During the Intended Treatment Period | 0.15 (0.06 to 0.37) | 0.37 (0.20 to 0.65) |
Major bleeding was adjudicated by an ICAC using criteria from the International Society on Thrombosis and Hemostasis (ISTH) and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or bleeding in a critical site or bleeding which is fatal. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Major Bleeding During the Treatment Period in Treated Participants | 0.47 (0.28 to 0.79) | 0.19 (0.08 to 0.42) |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis, if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for bleeding endpoints. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%): | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants | 2.26 (1.80 to 2.84) | 1.90 (1.48 to 2.43) |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. Major bleeding: acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or bleeding in a critical site or bleeding which is fatal. CRNM bleeding: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding; spontaneous hematuria; macroscopic gastrointestinal hemorrhage; rectal blood loss. Treatment Period=onset from first dose of study drug through 2 days after last dose of study drugs. Incidence: Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Composite of Major or Clinically Relevant Non-Major (CRNM) Bleeding During the Treatment Period in Treated Participants | 2.67 (2.16 to 3.29) | 2.08 (1.64 to 2.64) |
Bleeding was adjudicated by an ICAC using criteria from the ISTH. Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs, for bleeding endpoints. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of All Bleeding During the Treatment Period in Treated Participants | 7.73 (6.85 to 8.71) | 6.81 (5.99 to 7.73) |
A bilateral compression ultrasound (CUS) was performed between Days 5 and 14 for detection of asymptomatic proximal DVT unless a symptomatic VTE was confirmed prior. CUS was also performed on Day 30 ± 2 except for those participants who had a confirmed symptomatic VTE or proximal asymptomatic DVT prior to that time. Events adjudicated by ICAC. Intended Treatment Period=period that starts on day of randomization: period ends (for treated) at latter of a) 2 days after last dose of study drug and b) 32 days after first dose of study drug; (for not treated) period ends 32 days after randomization. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants).
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Incidence of Adjudicated Asymptomatic Proximal DVT With Onset During the Intended Treatment Period | 2.36 (1.80 to 3.09) | 2.12 (1.60 to 2.80) |
Treatment Period=includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs for AEs, and 30 days after last dose of study drugs for SAEs and deaths.
| participants | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| AEs | 1871 | 1910 |
| SAEs | 611 | 601 |
| Bleeding AEs | 244 | 221 |
| Discontinuations Due to AE | 290 | 262 |
| Deaths | 131 | 133 |
Diastolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken with the participant either sitting, standing, or supine.
| mmHg | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Day of Discharge from Hospital (N=1607, 1625) | -1.0 ± 12.69 | -0.4 ± 12.32 |
| Day 30 of Treatment + 2 (N=2227,2301) | 0.0 ± 12.91 | -0.5 ± 12.78 |
Systolic blood pressure was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Blood pressure was measured in millimeters of mercury (mmHg) and could have been taken either sitting, standing, or supine.
| mmHg | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Discharge from Hospital (N=1607, 1625) | -3.0 ± 19.12 | -2.4 ± 19.80 |
| Day 30 of Treatment + 2 (N=2227, 2301) | -2.3 ± 19.79 | -2.9 ± 20.61 |
Heart Rate was obtained during Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days. Heart rate was measured in beats per minute (bpm) and could have been taken with participants either sitting, standing, or supine.
| bpm | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Hospital Discharge (N=1606,1622) | -5.4 ± 14.08 | -5.1 ± 14.07 |
| Day 30 of treatment (N=2225,2299) | -4.0 ± 15.62 | -4.3 ± 14.83 |
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). Absolute (Abs). Hemoglobin: \>2 g/dL decrease compared to PreRx value or value \<=8 g/dL; Hematocrit: \<0.75\*PreRx; Erythrocytes: \<0.75\*PreRx c/µL; Leukocytes: \<0.75\*LLN or \> 1.25\*ULN, if PreRx \<LLN then use \<0.8\*PreRx or \>ULN, if PreRx \>ULN then use \>1.2\*PreRx or \< LLN; Platelet count: \< 100\*10\^9 c/L; ANC: \< 1.00\*10\^3 c/µL; Abs eosinophils: \> 0.75\*10\^3 c/µL; Abs Basophils: \> 400/MM\^3; Abs Monocytes \> 2000/MM\^3; Abs Lymphocytes: \< 0.750\*10\*3 c/ µL or \> 7.5\*10\^3 c/ µL. Samples were obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.
| participants | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Hemoglobin >2 g/dL decrease (N=2835, 2871) | 133 | 98 |
| Hematocrit <0.75*PreRx (N=2688, 2722) | 23 | 17 |
| Platelet Count < 100*10^9 c/L (N=2761, 2799) | 9 | 7 |
| Erythrocytes <0.75*PreRx c/µL (N=2697, 2730) | 28 | 16 |
| Leukocytes <0.75*LLN (N= 2835, 2869) | 64 | 55 |
| Leukocytes > 1.25*ULN (N=2835, 2869) | 331 | 283 |
| Abs Eosinophils > 0.75*10^3 c/µL (N=20, 24) | 1 | 1 |
| Abs Lymphocytes < 0.750*10*3 c/ µL (N=20, 24) | 4 | 2 |
| Abs Monocytes > 2000/MM^3 (N= 19, 25) | 1 | 0 |
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: \< 0.75\*LLN or \> 1.25\*ULN, or if PreRx \< LLN then use \< 0.75\* PreRx or \> ULN if PreRx \> ULN then use \> 1.25\*PreRx or \< LLN; Serum Calcium mg/dL Low/High: \< 0.8\*LLN or \> 1.2\*ULN, or if PreRx \< LLN then use \< 0.75\*PreRx or \> ULN if PreRx \> ULN then use \> 1.25\*PreRx or \< LLN; Serum Chloride mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use \< 0.9\*PreRx or \> ULN if PreRx \> ULN then use \> 1.1\*PreRx or \< LLN; Serum Potassium mEq/L: \< 0.9\*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use \< 0.9\*PreRx or \> ULN if PreRx \> ULN then use \> 1.1\*PreRx or \< LLN; Serum Sodium mEq/L: \< 0.95\*LLN or \> 1.05\*ULN, or if PreRx \< LLN then use \< 0.95\*PreRx or \> ULN if PreRx \> ULN then use \> 1.05\*PreRx or \< LLN. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.
| participants | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Calcium < 0.8*LLN (N=2861, 2893) | 6 | 8 |
| Calcium > 1.2*ULN (N=2861, 2893) | 3 | 3 |
| Chloride < 0.9*LLN (N=2861, 2886) | 25 | 25 |
| Chloride > 1.1*ULN (N=2861, 2886) | 5 | 1 |
| Bicarbonate < 0.75*LLN (N=2831, 2855) | 5 | 6 |
| Bicarbonate > 1.25*ULN (N=2831, 2855) | 6 | 4 |
| Potassium < 0.9*LLN (N=2851, 2878) | 61 | 58 |
| Potassium > 1.1*ULN (N=2851, 2878) | 140 | 137 |
| Sodium < 0.95*LLN (N=2862, 2888) | 23 | 25 |
| Sodium > 1.05*ULN (N=2862, 2888) | 9 | 6 |
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL \> 1.5\*ULN; Creatinine mg/dL: \> 1.5\*ULN; Alanine aminotransferase (ALT) U/L: \> 3\*ULN; Aspartate aminotransferase (AST) U/L: \> 3\*ULN; Alkaline phosphatase U/L: \> 2\*ULN; Bilirubin Direct mg/dL: \> 1.5\*ULN; Bilirubin Total mg/dL: \> 2\*ULN. Samples for laboratories obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) plus 2 days.
| participants | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Alkaline phosphatase U/L > 2*ULN(N=2866, 2895) | 35 | 47 |
| ALT U/L > 3*ULN (N=2827, 2861) | 23 | 33 |
| AST U/L > 3*ULN (N=2831, 2863) | 24 | 29 |
| Bilirubin Direct mg/dL > 1.5*ULN (N=2782, 2821) | 123 | 106 |
| Bilirubin Total mg/dL > 2*ULN (N=2853, 2884) | 17 | 15 |
| BUN mg/dL > 1.5*ULN (N=2864, 2891) | 194 | 188 |
| Creatinine mg/dL > 1.5*ULN (N=2862, 2892) | 150 | 156 |
Creatine kinase High: \>5\*ULN Units/Liter (U/L); Total Protein High/Low: \< 0.9 \*LLN or \> 1.1\*ULN, or if PreRx \< LLN then use 0.9\* PreRx or \> ULN if PreRx \> ULN then use 1.1 \*PreRx or \<LLN; Uric acid High: \> 1.5\* ULN, or if PreRx \> ULN then use \> 2 \*PreRx. Glucose Fasting: \<0.9\*LLN or \> 1.5\*ULN or if PreRx \< LLN then use \< 0.8\*PreRx or \> ULN, if PreRx \> ULN then use \>2.0\*PreRx. Samples obtained at Screening/Enrollment Visit (Day 1, prior to drug being administered), on the day of hospital discharge, Day 30 (last day of treatment) ± 2days.
| participants | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Glucose Fasting <0.9*LLN (N=284,287) | 5 | 3 |
| Glucose Fasting > 1.5*ULN (N=284,287) | 39 | 30 |
| Total Protein < 0.9 *LLN (N=2864, 2890) | 78 | 51 |
| Total Protein > 1.1*ULN (N=2864, 2890) | 16 | 8 |
| Creatine kinase >5*ULN U/L(N=2856, 2888) | 8 | 10 |
| Uric acid > 1.5* ULN (N=2862, 2889) | 47 | 44 |
Events of Special Interest include: adjudicated thrombocytopenia, adjudicated myocardial infarction (MI), adjudicated stroke, and adjudicated MI or stroke. Incidence determined by Event Rate (%): n/N\*100 (n=number with observation; N=total efficacy evaluable participants). Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drugs.
| Event Rate (%) | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| MI or stoke (N=3183, 3216) | 0.38 (0.21 to 0.67) | 0.37 (0.21 to 0.66) |
| MI (N=3184, 3217) | 0.22 (0.10 to 0.47) | 0.12 (0.04 to 0.34) |
| Stroke (N=3183, 3216) | 0.16 (0.06 to 0.38) | 0.25 (0.12 to 0.50) |
| Thrombocytopenia (N=3184, 3217) | 0.19 (0.08 to 0.42) | 0.09 (0.02 to 0.29) |
Special interest include: liver function test increases, AEs related to liver function, and neurologic AEs. Treatment Period includes measurements or events with onset from first dose of study drug through 2 days after the last dose of study drug when summarizing AEs and through 30 days after the last dose when summarizing SAEs.
| participants | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| Neurologic AEs | 45 | 42 |
| Neurologic SAEs | 5 | 1 |
| Liver-related AEs | 127 | 142 |
| Liver-related SAEs | 9 | 12 |
Liver function tests: Alanine aminotransferase (ALT) U/L; Aspartate aminotransferase (AST) U/L; Alkaline phosphatase U/L; Total Bilirubin (TBili) mg/dL. Elevations consist of \>3\*Upper Limit of Normal (ULN) for ALT and AST and elevation of \>2\*ULN for Bilirubin.
| participants | Apixaban 2.5 mg | Enoxaparin 40 mg |
|---|---|---|
| AST Elevation >3*ULN (N=2831, 2863) | 23 | 28 |
| ALT Elevation >3*ULN (N=2827, 2861) | 22 | 32 |
| AST + ALT >3*ULN on same date (N= 2827, 2861) | 14 | 13 |
| TBili >2*ULN (N= 2853, 2884) | 13 | 14 |
| ALT or AST >3*ULN + TBili >2*ULN (N=2818,2855) | 2 | 2 |
| ALT>3*ULN + TBili >2*ULN (N=2817, 2853) | 0 | 2 |
Collected over Day 1, first dose of study drug, to last dose of study drug plus 2 days (AEs), plus 30 days (SAEs, Deaths).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apix 2.5mg BID | — | 611/3,184 (19.2%) | 0/3,184 (0%) |
| Enox 40mg QD | — | 601/3,217 (18.7%) | 0/3,217 (0%) |
| Event | Apix 2.5mg BID | Enox 40mg QD |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 91/3184 | 103/3217 |
| PneumoniaInfections and infestations | 54/3184 | 40/3217 |
| Cardiac failureCardiac disorders | 50/3184 | 28/3217 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 26/3184 | 34/3217 |
| Cardiac failure congestiveCardiac disorders | 31/3184 | 32/3217 |
| Deep vein thrombosisVascular disorders | 25/3184 | 22/3217 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 17/3184 | 20/3217 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 18/3184 | 20/3217 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 7/3184 | 19/3217 |
| Atrial fibrillationCardiac disorders | 14/3184 | 15/3217 |
Randomized Participants
| Age, Continuous(years) | Apixaban 2.5 mg | Enoxaparin 40 mg | Total |
|---|---|---|---|
| Median | 68.0 (40 to 101) | 67.0 (40 to 98) | 67.0 (40 to 101) |
| Age, Customized(participants) | Apixaban 2.5 mg | Enoxaparin 40 mg | Total |
|---|---|---|---|
| Less than (<) 65 years | 1401 | 1411 | 2812 |
| Greater than, equal to (>=) 65 and < 75 years | 890 | 884 | 1774 |
| >= 75 years | 964 | 978 | 1942 |
| Sex: Female, Male(Participants) | Apixaban 2.5 mg | Enoxaparin 40 mg | Total |
|---|---|---|---|
| Female | 1629 | 1696 | 3325 |
| Male | 1626 | 1577 | 3203 |
| Region of Enrollment(participants) | Apixaban 2.5 mg | Enoxaparin 40 mg | Total |
|---|---|---|---|
| United States | 625 | 620 | 1245 |
| Philippines | 22 | 22 | 44 |
| Hong Kong | 26 | 26 | 52 |
| Taiwan | 8 | 7 | 15 |
| Spain | 51 | 50 | 101 |
| Ukraine | 270 | 276 | 546 |
| Chile | 65 | 65 | 130 |
| Israel | 168 | 168 | 336 |
| Russian Federation | 632 | 632 | 1264 |
| Colombia | 10 | 14 | 24 |
| Italy | 35 | 34 | 69 |
| India | 198 | 202 | 400 |
| France | 203 | 200 | 403 |
| Malaysia | 9 | 11 | 20 |
| Denmark | 49 | 54 | 103 |
| Australia | 51 | 49 | 100 |
| Peru | 119 | 121 | 240 |
| South Africa | 52 | 48 | 100 |
| Netherlands | 1 | 0 | 1 |
| Korea, Republic of | 33 | 33 | 66 |
| Turkey | 9 | 10 | 19 |
| Austria | 5 | 7 | 12 |
| United Kingdom | 195 | 194 | 389 |
| Hungary | 18 | 16 | 34 |
| Czech Republic | 53 | 56 | 109 |
| Mexico | 58 | 59 | 117 |
| Canada | 45 | 47 | 92 |
| Argentina | 78 | 77 | 155 |
| Brazil | 41 | 45 | 86 |
| Belgium | 21 | 22 | 43 |
| Poland | 57 | 60 | 117 |
| Singapore | 8 | 12 | 20 |
| Norway | 3 | 2 | 5 |
| Germany | 35 | 32 | 67 |
| Sweden | 2 | 2 | 4 |
| Participants with Risk Factors(participants) | Apixaban 2.5 mg | Enoxaparin 40 mg | Total |
|---|---|---|---|
| Previous Venous Thromboembolism (VTE) | 141 | 124 | 265 |
| Estrogenic Hormone Therapy | 49 | 27 | 76 |
| History of Malignancy | 312 | 320 | 632 |
| Chronic Heart Failure | 1531 | 1537 | 3068 |
Showing the first 100 of 297 sites across 35 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2007, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban